What are the recommended dosing regimens, contraindications, and monitoring parameters for atomoxetine in adults and in children/adolescents?

Atomoxetine Dosing, Contraindications, and Monitoring

Atomoxetine should be initiated at 0.5 mg/kg/day in children/adolescents ≤70 kg (or 40 mg/day in those >70 kg and adults), titrated after a minimum of 3 days to a target dose of 1.2 mg/kg/day (or 80 mg/day), with a maximum of 1.4 mg/kg/day or 100 mg daily, whichever is lower. 1

Dosing Regimens

Children and Adolescents (≤70 kg)

• Initial dose: 0.5 mg/kg/day
• Target dose: 1.2 mg/kg/day (after minimum 3 days)
• Maximum dose: 1.4 mg/kg/day or 100 mg/day, whichever is lower
• Administration: Can be given as single morning dose or divided into morning and late afternoon/evening doses 2

Children/Adolescents (>70 kg) and Adults

• Initial dose: 40 mg/day
• Target dose: 80 mg/day (after minimum 3 days)
• Maximum dose: 100 mg/day
• Dose escalation: May increase to 100 mg after 2-4 additional weeks if suboptimal response 1

Special Dosing Adjustments

CYP2D6 Poor Metabolizers or Strong CYP2D6 Inhibitor Use (e.g., paroxetine, fluoxetine, quinidine):

• Children ≤70 kg: Start 0.5 mg/kg/day, increase to 1.2 mg/kg/day only after 4 weeks if symptoms persist and initial dose tolerated
• Children >70 kg and adults: Start 40 mg/day, increase to 80 mg/day only after 4 weeks if needed 1

This adjustment is critical because approximately 7% of the population are poor metabolizers with significantly higher plasma levels and longer half-lives, increasing adverse effect risk 2. SSRIs can elevate serum atomoxetine levels through CYP2D6 inhibition 2.

Hepatic Impairment:

• Moderate (Child-Pugh Class B): Reduce initial and target doses to 50% of normal
• Severe (Child-Pugh Class C): Reduce to 25% of normal 1

Contraindications

Absolute Contraindications

1. Hypersensitivity to atomoxetine or product constituents 1
2. MAOI use within 2 weeks or other drugs affecting brain monoamine concentrations 1
3. Narrow-angle glaucoma 1
4. Pheochromocytoma or history thereof 1
5. Severe cardiovascular disorders that might deteriorate with clinically important increases in heart rate and blood pressure 1

Relative Contraindications/Warnings

• Preexisting cardiovascular disease/significant cardiac abnormalities: Atomoxetine generally should not be used in children/adolescents with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems 2
• Bipolar disorder: Screen for personal/family history before initiating; risk of emergent manic symptoms 2, 1
• History of urinary outflow obstruction: Use caution due to risk of urinary hesitancy/retention 3
• Epileptic seizures: Monitor closely 3
• Pregnancy/lactation: Use caution, though recent data shows minimal transfer into breast milk (0.19% RID) 4

Monitoring Parameters

Baseline Assessment

Before initiating atomoxetine:

• Cardiac history: Personal and family history of sudden death, cardiovascular symptoms, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, long QT syndrome 5
• Psychiatric screening: Personal/family history of bipolar disorder, mania, hypomania 1
• Physical examination: Blood pressure, heart rate, height, weight 5, 6
• Consider CYP2D6 genotyping: To guide dosing and predict response/tolerability 7, 8

Ongoing Monitoring

Critical Safety Monitoring (especially first few months or dose changes):

• Suicidality: Monitor closely for suicidal ideation, clinical worsening, and unusual behavioral changes in children/adolescents—this carries an FDA black box warning based on 12 placebo-controlled trials showing increased risk 2, 1. Notably, this risk was NOT observed in adult trials 2

Cardiovascular Monitoring:

• Heart rate and blood pressure at each visit
• Average increases: 1-2 bpm for HR, 1-4 mmHg for BP 5
• 5-15% of patients may experience substantial increases (≥20 bpm, ≥15-20 mmHg) 5
• Prompt cardiac evaluation if emergent cardiovascular symptoms develop 1

Growth Monitoring:

• Height and weight at each visit in pediatric patients
• Growth delays may occur in first 1-2 years but typically return to expected trajectories after 2-3 years 5

Hepatic Monitoring:

• Discontinue immediately if jaundice or laboratory evidence of liver injury develops 1
• Rare but severe liver injury can occur (including cases requiring transplantation) 9

Other Monitoring:

• Aggressive behavior or hostility (monitor for appearance/worsening) 2
• Psychotic or manic symptoms (consider discontinuation if new symptoms emerge) 2
• Priapism (rare but requires prompt medical attention) 2

Therapeutic Drug Monitoring (TDM)

Emerging evidence suggests TDM may optimize outcomes, particularly when combined with CYP2D6 genotyping 7, 8:

• For once-daily morning dosing: Peak plasma concentration ≥268 ng/mL associated with better response 7
• CYP2D6 intermediate metabolizers show 1.4-2.2 fold higher dose-corrected concentrations than extensive metabolizers 7
• Risk of CNS/GI adverse effects increases at concentrations ≥465-509 ng/mL in intermediate metabolizers 7

Common Adverse Effects

Children/Adolescents: Nausea, vomiting, fatigue, decreased appetite, abdominal pain, somnolence 2, 1

Adults: Constipation, dry mouth, nausea, fatigue, decreased appetite, dizziness, erectile dysfunction, urinary hesitation 1

Clinical Pearls

• Atomoxetine can be discontinued without tapering (unlike alpha-2 agonists) 1
• Capsules must be swallowed whole, not opened 1
• Can be taken with or without food 1
• Maintenance therapy: Periodically reevaluate long-term need; controlled trials support continued benefit in responders 1
• Real-world dosing often suboptimal: Average adult dose ~60 mg/day versus recommended 80 mg/day target; adequate duration at target dose (4-6 weeks) essential before judging efficacy 10
• No abuse potential: Negligible risk of misuse, making it suitable for patients with substance use concerns 11